

**Item: 8.3**

<b>Report to:</b>	NHS Hull Clinical Commissioning Group Board
<b>Date of Meeting:</b>	23 November 2018
<b>Title of Report:</b>	Research & Development (R&D) Status Report: April 2018– October 18
<b>Presented by:</b>	Sarah Smyth, Director of Quality & Clinical Governance / Executive Nurse
<b>Author:</b>	Danielle Hook – R & D Manager Validated by Marie Girdham – R & D Lead Manager (Humber)

**STATUS OF THE REPORT:**

To approve	<input type="checkbox"/>	To endorse	<input type="checkbox"/>
To ratify	<input type="checkbox"/>	To discuss	<input type="checkbox"/>
To consider	<input type="checkbox"/>	For information	<input type="checkbox"/>
To note	<input checked="" type="checkbox"/>		

**PURPOSE OF REPORT:**  
For the Hull CCG Board to endorse and discuss the R&D Status Report.

**RECOMMENDATIONS:**

a The Board are asked to note the R&D Status Report

**REPORT EXEMPT FROM PUBLIC DISCLOSURE** No  Yes

If yes, detail grounds for exemption

**CCG STRATEGIC OBJECTIVE** *(See guidance notes on page 4)*

1, 8 and 12 (see page 4)

*Short summary as to how the report links to the CCG's strategic objectives*

NHS Hull CCG is legally required to support and promote research and the use of research evidence (Health and Social Care Act, 2012).

<b>IMPLICATIONS:</b> (summary of key implications, including risks, associated with the paper),	
Finance	Implications linked to financial planning and financial reporting of funds used towards supporting R&D, for instance Excess Treatment Costs (ETCs).
HR	None
Quality	R&D is indicative of being a quality measure in terms of outcomes and service delivery as demonstrated through the CCG's quality accounts.
Safety	Necessary assurances that all regulatory approvals are in place and that patient safety in research is paramount.

**ENGAGEMENT:** (Explain what engagement has taken place e.g. Partners, patients and the public prior to presenting the paper and the outcome of this)

All research projects supported by NHS Hull CCG require demonstrating patient involvement in the project design, rationale and/or participation including provision of full information and formal consent procedures consistent with the UK Policy Framework for Health and Social Care (2017).

**LEGAL ISSUES:** (Summarise key legal issues / legislation relevant to the report)

NHS Hull CCG is legally required to support and promote research and the use of research evidence (Health and Social Care Act, 2012).

Mandated to fund ETCs as part of normal commissioning arrangements (NHS England, 2015).

**EQUALITY AND DIVERSITY ISSUES:** (summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). **All** reports relating to new services, changes to existing services or CCG strategies / policies **must** have a valid EIA and will not be received by the Committee if this is not appended to the report)

	<b>Tick relevant box</b>
An Equality Impact Analysis/Assessment is not required for this report.	X
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

**THE NHS CONSTITUTION:** (How the report supports the NHS Constitution)

The NHS Constitution confirms the commitment of the NHS "to the promotion and conduct of research." NHS Hull CCG is fully compliant with this provision of the NHS Constitution.